Horizon Therapeutics Public Limited Company - Ordinary Shares (HZNP): Price and Financial Metrics
Horizon Therapeutics Public Limited Company - Ordinary Shares (HZNP)
Today's Latest Price: $77.26 USD
Updated Oct 28 4:00pm
Add HZNP to WatchlistSign Up
POWR Components:
Trade Grade Buy & Hold Grade Peer Grade Industry Rank
Industry Rank:
Ranked of 240 in Medical - Pharmaceuticals
See all "A" rated Strong Buy stocks
HZNP Stock Summary
- HZNP has a higher market value than 88.79% of US stocks; more precisely, its current market capitalization is $15,953,192,867.
- Price to trailing twelve month operating cash flow for HZNP is currently 50.5, higher than 92.96% of US stocks with positive operating cash flow.
- With a price/sales ratio of 10.51, Horizon Therapeutics Public Ltd Co has a higher such ratio than 86.8% of stocks in our set.
- If you're looking for stocks that are quantitatively similar to Horizon Therapeutics Public Ltd Co, a group of peers worth examining would be EXAS, AYX, NTRA, BL, and AKAM.
- Visit HZNP's SEC page to see the company's official filings. To visit the company's web site, go to www.horizontherapeutics.com.
HZNP Stock Price Chart Interactive Chart >
HZNP Price/Volume Stats
| Current price | $77.26 | 52-week high | $86.67 |
| Prev. close | $78.15 | 52-week low | $23.81 |
| Day low | $74.79 | Volume | 1,722,300 |
| Day high | $77.91 | Avg. volume | 2,210,425 |
| 50-day MA | $76.90 | Dividend yield | N/A |
| 200-day MA | $52.25 | Market Cap | 15.95B |
Horizon Therapeutics Public Limited Company - Ordinary Shares (HZNP) Company Bio
Horizon Pharma plc engages in identifying, developing, acquiring or in-licensing, and commercializing medicines for the treatment of arthritis, pain, inflammatory, and/or orphan diseases in the United States and internationally. The company was founded in 2005 and is based in Dublin, Ireland.
HZNP Price Forecast Based on DCF Valuation
| Current Price | DCF Fair Value Target: | Forecasted Gain: |
| $77.26 | $45.26 | -41% |
The table below illustrates the output of a discounted cash flow forecast using a variety of scenarios for Horizon Therapeutics Public Ltd Co. To summarize, we found that Horizon Therapeutics Public Ltd Co ranked in the 34th percentile in terms of potential gain offered. Our DCF analysis suggests the stock is overvalued by about 41.17%. In terms of the factors that were most noteworthy in this DCF analysis for HZNP, they are:
- The compound growth rate in the free cash flow of Horizon Therapeutics Public Ltd Co over the past 5.44 years is 0.45%; that's better than 74.17% of cash flow producing equities in the Healthcare sector, where it is classified.
- The business' balance sheet reveals debt to be 7% of the company's capital (with equity being the remaining amount). Approximately merely 18.78% of US stocks with free cash flow have a lower reliance on debt in their capital structure.
- Horizon Therapeutics Public Ltd Co's effective tax rate, as measured by taxes paid relative to net income, is at 115 -- greater than 97.77% of US stocks with positive free cash flow.
| Terminal Growth Rate in Free Cash Flow | Return Relative to Current Share Price |
| 0% | -43% |
| 1% | -42% |
| 2% | -41% |
| 3% | -41% |
| 4% | -40% |
| 5% | -40% |
EDAP, MD, CMD, OSMT, and CRL can be thought of as valuation peers to HZNP, in the sense that they are in the Healthcare sector and have a similar price forecast based on DCF valuation.
Loading social stream, please wait...